13F HOLDINGS REPORT
ARCH Venture Management, LLC
Quarter ended Q4 2024 · Filed February 14, 2025 · Accession 0001012975-25-000089
Total Value
$230.2M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BEAM THERAPEUTICS INC. | BEAM | 4,540,132 | $112.6M | 48.91% |
| 2 | RAPPORT THERAPEUTICS, INC. | RAPP | 3,728,738 | $66.1M | 28.73% |
| 3 | ERASCA, INC. | ERAS | 11,055,554 | $27.7M | 12.05% |
| 4 | VERVE THERAPEUTICS, INC. | 92539P101 | 2,008,809 | $11.3M | 4.92% |
| 5 | GOSSAMER BIO, INC. | GOSS | 8,055,916 | $7.3M | 3.17% |
| 6 | SINGULAR GENOMICS SYSTEMS, INC. | 82933R308 | 126,630 | $2.5M | 1.07% |
| 7 | Q32 BIO INC. | QTTB | 320,482 | $1.1M | 0.48% |
| 8 | UNITY BIOTECHNOLOGY, INC. | UNTCW | 1,004,817 | $981,103 | 0.43% |
| 9 | CERO THERAPEUTICS HOLDINGS, INC. | 71902K105 | 9,393,561 | $563,614 | 0.24% |